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Addressing intracellular targets is a challenging task that requires potent molecular
transporters capable to deliver various cargos. Herein, we report the synthesis of
hydrophobic macrocycles composed of both amino acids and peptoid monomers.
The cyclic tetramers and hexamers were assembled in a modular approach using solid
as well as solution phase techniques. To monitor their intracellular localization, the
macrocycles were attached to the fluorophore Rhodamine B. Most molecular
transporters were efficiently internalized by HeLa cells and revealed a specific
accumulation in mitochondria without the need for cationic charges. The data will
serve as a starting point for the design of further cyclic peptoid-peptide hybrids
presenting a new class of highly efficient, versatile molecular transporters.
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INTRODUCTION
Biological membranes envelop intracellular structures, protect them from harmful substances and
enable diverse physiological processes. The unique function of these phospholipid bilayers is crucial
for all processes of life but also hampers the intracellular delivery of therapeutics or other cargos. The
efficient internalization of a certain compound is a key step for both pharmaceutical and basic
research. Thus, molecules that overcome the physiological barrier, so-called molecular transporters,
are constantly needed not only to resolve and understand the fascinating processes of life but also to
provide treatments poor in side effects.
In the late 1980s, the capability of the Trans-Activator of Transcription (Tat) protein of the
Human Immunodeficiency Virus (HIV) to overcome cellular barriers without any receptor
interaction was discovered. (Green and Loewenstein, 1988; Frankel and Pabo, 1988). Thereby,
the foundation for a new compound class, the cell-penetrating peptides (CPPs), was laid. Since then,
plenty of different CPPs capable to transport diverse cargos across cellular membranes have been
published and outlined in numerous comprehensive reviews. (Koren and Torchilin, 2012; Copolovici
et al., 2014; Guidotti et al., 2017; Kalafatovic and Giralt, 2017; Taylor and Zahid, 2020; Falanga et al.,
2020; Desale et al., 2021) Although a lot of research is focused on CPPs, some questions remain open.
As an example, the uptake mechanism of these molecular transporters is still not fully understood.
(Richard et al., 2003; Madani et al., 2011; Ruseska and Zimmer, 2020). Thus, the efficiency
enhancement of cellular uptake is one of many subjects of current research. (Nadal Bufí and
Henriques, 2020; Fazil et al., 2020; Yin et al., 2020). It has already been shown that a rigidification of
the spatial structure increases the activity of some CPPs due to improved interactions with the
phospholipid bilayer, limited off-target effects, and a lower entropy penalty. (Lättig-Tünnemann
et al., 2011; Nischan et al., 2015; Dougherty et al., 2019; Park et al., 2019)Moreover, the incorporation
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of certain peptidomimetics could enhance both cellular uptake
efficiency and metabolic stability. (Kölmel et al., 2012; Huang
et al., 2012; Jing et al., 2012; Vollrath et al., 2013; Koelmel et al.,
2014; Dougherty et al., 2019) As CPPs resemble endogenous
structures, they are prone to fast proteolytic degradation.
(Goodwin et al., 2012; Zhang et al., 2020) Peptidomimetics
such as peptoids mimic the structural and functional
features of peptides while enhancing their bioavailability.
(Dohm et al., 2011; Simon et al., 1992; Zuckermann et al.,
1992; Zuckermann, 2011) Peptoids are N-substituted
oligoglycines are readily accessible via well-established solid-
phase synthesis techniques. (Zuckermann, 2011) Formally,
they solely differ from peptides in the location of their side
chain which is moved from the α-carbon to the nitrogen atom
(Figure 1). However, this shift has a major impact on the
conformational flexibility and, thus, on the spatial structure of
peptoids (Yoo and Kirshenbaum, 2008; Zuckermann, 2011;
Kirshenbaum and Zuckermann, 2019).
Besides the capability to form hydrogen bonds, the chirality at
the α-carbon is lost when transforming peptides to peptoids.
Interestingly, it has been shown that the absence of these features
can even increase the efficiency of cellular uptake. (Wender et al.,
2000; Goun et al., 2006; Tan et al., 2008; Schwochert et al., 2015)
Together with their high stability against enzymatic degradation,
cell-penetrating peptoids (CPPos) constitute promising tools for
cargo delivery.
So far, mainly positively charged CPPos have been synthesized
with cellular uptake specificity for endosomes, the cytosol, or the
nucleus. (Murphy et al., 1998; Wender et al., 2000; Wright et al.,
2003; Schröder et al., 2007; Schröder et al., 2008; Eggenberger
et al., 2009; Unciti-Broceta et al., 2009; Huang et al., 2012; Kölmel
et al., 2012; Sternberg et al., 2013; Kölmel et al., 2014; Marouseau
et al., 2017) The incorporation of a critical amount of lipophilic
side chains led to a specific accumulation in mitochondria.
(Kölmel et al., 2012; Nam et al., 2018) It was stated, that a
cationic charge may be a prerequisite for interaction with the
negatively charged head groups of the phospholipid bilayer
and subsequent cellular uptake through the plasma
membrane. (Wender et al., 2000; Peretto et al., 2003;
Madani et al., 2011; Koren and Torchilin, 2012; Guidotti
et al., 2017) Shin et al. (Shin et al., 2018) showed that the
efficiency of this cellular uptake is significantly increased
after cyclization of linear CPPos.
As a defined three-dimensional structure caused by cyclization
has proved to be beneficial for cellular uptake, (Lättig-
Tünnemann et al., 2011; Nischan et al., 2015; Shin et al., 2018;
Dougherty et al., 2019; Park et al., 2019), we herein report the
synthesis of macrocyclic tetramers and hexamers as novel
molecular transporters. The macrocycles are composed of both
alkylated glycine monomers and amino acids to maintain steric
information that may be crucial for high biological activity.
(Agrawal et al., 2007; Henriques et al., 2019) These cyclic
hybrids constitute a promising substance class combining the
unique selectivity of peptides with the outstanding bioavailability
of peptoids (Olsen, 2010; Schwochert et al., 2015).
FIGURE 1 | Phenylalanine (Green and Loewenstein, 1988) as an
example for an amino acid as the building block of a peptide (A) and N1ph
(Frankel and Pabo, 1988) as an example for an alkylated glycine monomer (B).
SCHEME 1 | Synthetic approach for the assembly of linear precursors on solid support. [A]: Fmoc-protected amino acid, N,N′-diisopropylethylamine (DIPEA),
N-methyl-2-pyrrolidone (NMP), 21°C, 16 h; [B]: piperidine, dimethylformamide (DMF), 21°C, 3 × 5 min; [C]: Fmoc-protected amino acid, N,N’-diisopropylcarbodiimide
(DIC), hydroxybenzotriazole, NMP, 21°C, 4 h; [D]: bromoacetic acid, DIPEA, DMF, 21°C, 1 h; [E]: amine, DMF, 21°C, 1–16 h; [F]: bromoacetic acid, DIC, DMF, 21°C, 30
min; [G]: hexafluoroisopropanol, methylene chloride, 21°C, 16 h.
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RESULTS AND DISCUSSION
Macrocyclic tetramers and hexamers were synthesized in a
multistep procedure using solid and solution phase methods.
The synthetic approach involved the assembly of linear
precursors on solid supports following the submonomer
method published by Zuckermann (Zuckermann et al., 1992)
as well as the solid phase peptide synthesis (SPPS) described by
Merrifield (Merrifield, 1963). A 2-chlorotrityl chloride
polystyrene resin (3) served as solid support (Scheme 1).
The submonomer method requires an acetylation step using a
haloacetic acid followed by a substitution implementing the desired
side chain. (Zuckermann et al., 1992) Thus, bromoacetic acid was
either attached to the resin under basic conditions (→ 7) or to the
FIGURE 2 | Alkylated glycine monomers 2 and 12–14 used for the synthesis of molecular transporters and their applied designation.
FIGURE 3 | Macrocyclic hybrids 15–24 composed of alkylated glycine monomers and amino acids that were assembled via a combination of solid and solution
phase methods.
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growing oligomer chain using diisopropylcarbodiimide (DIC) as a
coupling reagent. A certain amine was added allowing for the
assembly of an alkylated glycinemonomer (→ 8). The possibility to
incorporate any amine gives rise to various side chains and, thus,
easily tunable properties of the resulting peptoids. For the design of
molecular transporters, the substitution step was performed with
four different amines that led to the assembly of the alkylated
glycine monomers N1ph (2), N1phpCl (12), N3m (13), and N4am
(14, Figure 2). The former ones were empirically chosen to
examine the influence of lipophilicity on the biological activity
of the respective macrocycles. Thereby, all lipophilic monomers
should allow for an accumulation in mitochondria. (Kölmel et al.,
2012; Nam et al., 2018) The peptoidmonomerN4am (14) served as
conjugation site for the fluorophore Rhodamine B.
The SPPS was performed using Fmoc-protected amino acids.
They were analogously attached to the resin (→ 4) under basic
conditions or to the growing linear precursor using DIC. To avoid
racemization at the α-carbon, hydroxybenzotriazole was added for
amino acid couplings. The temporary Fmoc-protecting group was
cleavedwith piperidine after coupling (→ 5). The combination of both
solid-phase methods enabled the straightforward synthesis of linear
hybrids composed of alkylated glycine monomers as well as amino
acids. The linear precursors 11 were cleaved from the resin under
mildly acidic conditions releasing a carboxylic acid at the C-terminus.
The subsequent head-to-tail cyclization using the crude linear
precursors and [dimethylamino(triazolo[4,5-b]pyridine-3-yloxy)
methylidene]-dimethylazanium hexafluorophosphate (HATU)
as potent coupling agent was performed under high dilution
conditions to avoid favored side reactions like dimerizations.
(Aldrich et al., 2011; Thakkar et al., 2013) Thus, the respective
linear precursor was added dropwise to an extensively stirred
solution of HATU. Thereby, the concentration of the added linear
peptide-peptoid hybrid solution did not exceed 7.50 mM. After
eleven or respectively fifteen reaction steps, the macrocycles were
purified via preparative reversed-phase high performance liquid
chromatography (HPLC). Product formation was confirmed via
matrix-assisted laser desorption/ionization-time of flight
(MALDI-TOF) mass spectrometry and subsequent nuclear
magnetic resonance (NMR) spectroscopy. The synthetic
protocol yielded the macrocyclic compounds 15–24 (Figure 3).
SCHEME 2 | Conjugation of the chromophore Rhodamine B to a cyclic hybrid exemplarily shown for macrocycle 15. [A] Rhodamine B, HATU, DIPEA, DMF,
36 h, 21°C.
TABLE 1 | Isolated yields and purities of the luminescent conjugates 15-Rhod to
24-Rhod.











TABLE 2 | IC50 values of the macrocycles 15–24 as well as their conjugates 15-
Rhod to 24-Rhod.
Macrocycle IC50 [µM] Conjugate IC50 [µM]
15 >50 15-Rhod >50
16 >50 16-Rhod 30
17 >50 17-Rhod >50
18 >50 18-Rhod 33
19 >50 19-Rhod 34
20 >50 20-Rhod >50
21 >50 21-Rhod 36
22 >50 22-Rhod 44
23 20 23-Rhod 6
24 >50 24-Rhod 26
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Seven cyclic tetramers (15–21) and three cyclic hexamers
(22–24) were successfully synthesized. Every macrocycle is
composed of several alkylated glycine monomers and up to two
amino acids. The hybrids share aromatic as well as aliphatic residues
and an aminobutyl side chain. In every case, an aromatic amino acid
represents the N-terminus of the linear precursor. It was assumed
that the higher nucleophilicity of a primary amine might be
beneficial for the subsequent ring closure reaction.
Regardless of their size and composition, all macrocycles were
isolated in similar yields (14% ± 5) and satisfying purities (94% ±
5). For the assembly of hybrids 15–17, an alkylated glycine
monomer was attached to the solid support. Compared to
tetramers 18–21 that were immobilized via an amino acid, the
yields of the respective linear precursors were slightly decreased:
While the crude linear tetramers of macrocycles 18–21 were
isolated in 70% ± 14 yields, the precursors of tetramers 15–17
yielded 41% ± 5. It is noteworthy, that either the attachment of an
alkylated glycine monomer to the solid support or the number of
alkylated glycine monomers might be decisive for this discrepancy.
Cyclization occurred to be more efficient for hybrids 15–17,
possibly due to increased conformational flexibility, (Yoo et al.,
2010; De Riccardis, 2020), resulting in similar overall yields.
As the attachment of an amino acid to the solid support
proved to be more efficient, linear hexamers were immobilized
via L-phenylalanine (1). Due to the additional reaction steps, the
yields of the crude linear hexamers were lowered (49% ± 13).
Nevertheless, every linear precursor was synthesized in a
sufficient quantity for cyclization. Depending on the amount
of the linear precursor isolated, cyclization was carried out by the
addition of a 3.25–7.50 mM solution of the respective linear
hybrid. However, no effects on the efficiency of the ring
closure were observed within this concentration range.
With the macrocyclic hybrids in hands, ten hydrophobic
molecular transporters were synthesized. As a cargo, the
potent fluorophore Rhodamine B was chosen. The
chromophore is known for its biocompatibility and is widely
used in biological research. (Lavis and Raines, 2008) Rhodamine
B was attached via its carboxylic moiety to the aminobutyl side
chains of the single macrocycles (Scheme 2).
The conjugation of Rhodamine B was conducted by the
cyclization of linear precursors using HATU as a reliable
activating agent. The labeling occurred in moderate yields
(27% ± 5) and excellent purities (Table 1).
The cytotoxicity of the macrocyclic hybrids 15–24, as well as
their conjugates 15-Rhod to 24-Rhod, was examined using a
standard MTT assay in human epithelial cervix carcinoma
(HeLa) cells. This colorimetric assay displays the cell viability
based on their capability to reduce the tetrazolium dye 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
(Mosmann, 1983; Tolosa et al., 2015) After treatment of HeLa
cells with different concentrations of the respective macrocycles
15–24 (0.50─50 µM) for 72 h, no significant cytotoxic effects were
observed. Most hybrids resulted in IC50 > 50 µM. However, in most
cases the attachment of the chromophore Rhodamine B slightly
increased the cytotoxicity of the respective molecular transporters
15-Rhod–24-Rhod (Table 2). As shown by many research groups
FIGURE 4 | Localization of the macrocyclic conjugates 15-Rhod to 24-
Rhod in HeLa cells. After incubation with a 5.0 µM solution of the respective
transporters for 5 h, the cellular uptake wasmonitored via fluorescent confocal
microscopy (Rhodamine B labeled hybrids: λExc  532 nm, λEm 
570–620 nm; MitoTracker
®
Green: λExc  488 nm, λEm  490–540 nm;
Hoechst 33,342: λExc  405 nm, λEm  430–490 nm). Counterstaining with
MitoTracker
®
Green visualized mitochondria (green). Staining with 2 μg/ml
Hoechst 33,342 indicated nuclei (blue). Scale bar: 10 µm.
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that Rhodamine B by itself is not efficiently entering the cells
showing therefore an LD50 > 50 μM, we assume that this the
toxicity of the Rhodamine moiety might be higher when
increasingly localizing in the mitochondria to a higher amount.
Conjugate 23-Rhod is the only hybrid with an IC50 value in a
single-digit micromolar range (IC50  6 µM). Its parent
macrocycle 23 turned out to be the most cytotoxic hybrid
tested (IC50  20 µM). Considering every cyclic hybrid, the
incorporation of the alkylated glycine monomer N1phpCl (12)
was decisive for the cytotoxicity of the respective macrocycles: the
higher the amount of N1phpCl building blocks, the lower the
viability of the HeLa cells after treatment. However, comparing
the macrocyclic transporters 19-Rhod and 20-Rhod, the
substitution of two N1ph (2) monomers by two N1phpCl
building blocks led to a decrease of cytotoxicity.
As 15-Rhod to 24-Rhod were not toxic at 5 µM the following
transport experiments were carried out using this concentration.
To study their cellular uptake and organellar localization, HeLa
cells were treated with 5 µM of the cyclic conjugates 15-Rhod to
24-Rhod for 5 h and eventually imaged using confocal microscopy
(for experimental details, see supplemental Material).
The molecular transporters 15-Rhod, 16-Rhod, 20-Rhod-22-
Rhod, and 24-Rhod were efficiently taken up by the cells and
localized to different organelles due to their differences in their
side-chain corona. Counterstaining of mitochondria using the
mitochondrial marker MitoTracker Green® gave evidence of a
mitochondrial accumulation for conjugates 15-Rhod to 17-Rhod
and 19-Rhod to 24-Rhod (Figure 4).
A high cellular uptake efficiency, as well as mitochondrial
specificity, was observed for the molecular transporters 15-Rhod,
16-Rhod, 20-Rhod to 22-Rhod, and 24-Rhod. Mitochondrial
accumulation was also shown for conjugates 17-Rhod, 19-Rhod
and 23-Rhod, however, their cellular uptake was significantly less
efficient. An interesting discrepancy in the uptake efficiency was
observed when comparing the molecular transporters 18-Rhod and
21-Rhodwhich are both characterized by the amino acid L-tyrosine.
While 18-Rhod containing two benzyl side chains was not
internalized by the HeLa cells, conjugate 21-Rhod, in which
both benzyl moieties were replaced by two aliphatic side chains,
was efficiently taken up. By comparison of the cyclic tetramers 15-
Rhod and 17-Rhod as well as the hexamers 22-Rhod and 24-Rhod,
the substitution of aromatic residues by aliphatic side chains had no
positive effect on the cellular efficiency. 17-Rhod was even less
internalized than 15-Rhod. Regarding substitutions of N1ph (2) by
its halogenated relative N1phpCl (13), no conclusive effects were
observed as well. Conjugates 15-Rhod and 16-Rhod showed a
similar cellular uptake efficiency, while an exchange of twoN1ph (2)
side chains by N1phpCl (13) increased the uptake of the molecular
transporter 20-Rhod compared to conjugate 19-Rhod. However,
the halogenation of three N1ph (2) building blocks led to a
significantly decreased cellular uptake efficiency which becomes
evident by comparison of hexamers 22-Rhod and 23-Rhod.
Themolecular transporters 15-Rhod, 20-Rhod and 22-Rhod are
characterized by low cytotoxicity, efficient cellular uptake, and high
specificity. Thus, they represent the most promising cyclic hybrids
capable of the transport of different cargos into mitochondria. The
data obtained support previous studies on peptides and peptoids
indicating that a certain amount of lipophilic residues may be crucial
for mitochondrial targeting. (Kölmel et al., 2012; Nam et al., 2018)
Besides, the data prove that no cationic charges are needed for
mitochondrial localization. The capability of hydrophobic structures
to function as molecular transporters is also known for so-called
hydrophobic CPPs. However, only a few members of this substance
class have been discovered yet. (Xie et al., 2020; Desale et al., 2021) It
is assumed, that hydrophobic CPPs may penetrate cellular
membranes in a direct, energy-independent manner dispensing
with endocytosis. (Gao et al., 2002; Gao et al., 2011; Nakayama
et al., 2011; Guidotti et al., 2017; Tian et al., 2017) The latter leads to a
major challenge as molecular transporters might not escape the
endosomes and get degraded instead of reaching their designated
targets. (Nadal Bufí andHenriques, 2020) As exemplaryly shown for
the macrocyclic transporter 22-Rhod, the mitochondrial uptake is
occurring at 37°C as well as at 4°C (see supplemental material,
Supplementary Figure S1). The efficient internalization at a low
temperature led us to the assumption that 22-Rhod might directly
penetrate the cell membrane. However, the uptake mechanism of
macrocyclic hybrids will be further examined.
The versatile substance class of peptide-peptoidmacrocycles shows
high potential as molecular transporters. Their specific targeting of
mitochondria paves the way for the treatment of various diseases that
are associated with these organelles. (Malty et al., 2015; Javadov et al.,
2020; Tan and Finkel, 2020) Structural studies onmacrocyclic hybrids
as well as an establishment of a comprehensive structure-activity
relationship will henceforth enlarge their applicability as versatile tools
in pharmaceutical and basic research.
CONCLUSION
Ten macrocyclic peptide-peptoid hybrids were synthesized in a
straightforward approach using solid and liquid phase techniques.
Their unique structure combines the advantages of both peptides
and peptoids. The conformational constraints introduced by chiral
amino acids as well as the cyclization of their backbone render
them promising model structures for selective compounds. Their
capability to form hydrogen bonds makes them soluble in an
aqueous environment. Furthermore, the incorporation of
N-alkylated glycine monomers resulting in a hybrid structure
increases their polarity and variability by allowing for the
incorporation of plenty of different side chains and easily
tunable properties. The hydrophobic molecular transporters
presented selectively accumulated in mitochondria without the
need for additional cationic charges. Thus, their uptakemechanism
might differ from known CPPs and CPPos. Further studies on
these versatile structures will reveal their potential as selective and
highly efficient molecular transporters.
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